Evidence map›Paper›PMID 39569383›Full record

ArticleiScience2024

Inhibiting AMPA receptor signaling in oligodendrocytes rescues synapse loss in a model of autoimmune demyelination.

Gabrielle M Mey, Kirsten S Evonuk, John Shelestak, Muhammad Irfan, Laura M Wolfe, Sophia E Laye, Dorothy P Schafer, Tara M DeSilva

Abstract read
In one paragraph

Article in iScience, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Gabrielle M MeyDepartment of Neurosciences, Cleveland Clinic and Case Western Reserve University, Cleveland, OH, USA.
Kirsten S EvonukDepartment of Neurosciences, Cleveland Clinic and Case Western Reserve University, Cleveland, OH, USA.
John ShelestakDepartment of Neurosciences, Cleveland Clinic and Case Western Reserve University, Cleveland, OH, USA.
Muhammad IrfanDepartment of Neurosciences, Cleveland Clinic and Case Western Reserve University, Cleveland, OH, USA.
Laura M WolfeDepartment of Neurosciences, Cleveland Clinic and Case Western Reserve University, Cleveland, OH, USA.
Sophia E LayeDepartment of Neurosciences, Cleveland Clinic and Case Western Reserve University, Cleveland, OH, USA.
Dorothy P SchaferDepartment of Neurobiology, Brudnik Neuropsychiatric Research Institute, University of Massachusetts Medical School, Worcester, MA, USA.
Tara M DeSilvaDepartment of Neurosciences, Cleveland Clinic and Case Western Reserve University, Cleveland, OH, USA.

Funding

RESOURCE/SERVICE CORE C - MOLECULAR INFORMATICS MODULEP30EY025585 · NEI · CLEVELAND CLINIC LERNER COM-CWRU · PI Brian D Perkins · 2016 to 2026
$7.7M
Mechanisms of Activity-Dependent Myelination in the Visual SystemR01EY025687 · NEI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI DESILVA, TARA MARIA · 2015 to 2019
$2.4M
Mechanisms of retinal degeneration in neuroinflammatory demyelinating diseasesR01EY032342 · NEI · CLEVELAND CLINIC LERNER COM-CWRU · PI DESILVA, TARA MARIA · 2021 to 2024
$1.6M
Cole Eye Institute Vision Science Training ProgramT32EY024236 · NEI · CLEVELAND CLINIC LERNER COM-CWRU · PI ANAND-APTE, BELA · 2015 to 2025
$1.0M
NEI NIH HHS P30 EY025585NEI NIH HHS R01 EY025687NEI NIH HHS R01 EY032342NEI NIH HHS T32 EY024236
6 · The paper itself

Abstract

Multiple sclerosis (MS) is initially characterized by myelin and axonal damage in central nervous system white matter lesions, but their causal role in synapse loss remains undefined. Gray matter atrophy is also present early in MS, making it unclear if synaptic alterations are driven by white matter demyelinating lesions or primary gray matter damage. Furthermore, whether axonal pathology occurs secondary to or independent of demyelination to drive synaptic changes is not clear. Here, we address whether reducing demyelination by selectively manipulating glutamatergic signaling in mature oligodendrocytes (OLs) preserves synapses in experimental autoimmune encephalomyelitis (EAE), a preclinical model of demyelinating disease. We demonstrate that inducible reduction of the GluA4 AMPA-type glutamate receptor subunit selectively in mature (OLs) reduces demyelination and axonal injury, preserves synapses, and improves visual function during EAE. These data link demyelination to the pathophysiology of synaptic loss with therapeutic implications for both motor and cognitive disability in MS.

Indexed as

Cell biologyImmunologyNeuroscience

Identifiers

PMID39569383
PMCPMC11577175

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.